News

BiTE antibodies: Bayer does it again
Enlarge image

BusinessGermany

BiTE antibodies: Bayer does it again

25.04.2012 - Even after the takeover of German-American Micromet Inc. by Amgen, Bite antibody technology remains interesting for other pharma partners.

Berlin/Martinsried  –  Bayer HealthCare has agreed to extend its collaboration with Amgen Research GmbH, as the former Micromet site in Munich is called today. Bayer and its partner will develop another new Bispecific T cell Engager antibody against an undisclosed target expressed in multiple tumours. The German pharma had forged a first option, collaboration and license agreement with Micromet in January 2009 to discover and develop a novel BiTE antibody targeting PSMA (prostate specific membrane antigen) for the treatment of patients with prostate cancer.  Amgen acquired Micromet in March this year for US-$1.2bn and promised to keep the German site as its largest research centre outside the US. Under the terms of the present agreement, Bayer will collaborate with Amgen Research from the research phase through to the completion of Phase I clinical trials, upon which Bayer will assume full control of further development and commercialisation of the product candidate. The cooperation also includes evaluation of BiTE antibodies with an extended serum half-life. Financial details of the collaboration were not disclosed. Meanwhile, the development of the initial BiTE antibody resulting from the 2009 collaboration progresses according to plan and the initiation of the clinical Phase I trial could start as early as in the second half of 2012.

http://www.european-biotechnology-news.com/news/news/2012-02/bite-antibodies-bayer-does-it-again.html

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014